Referenzen
Produkte Transfektion
Kostenlose Testsamples
Anwendungshinweise:
Im „Transfection Reagent Selection Guide“ können Sie durch Filterfunktionen z.B. für Ihre Kombination aus zu transfizierender Zelle und Nukleinsäure die Liste vorhandener Referenzen durchsuchen. Ebenso können Sie im Feld „Referenzen durchsuchen“ am Anfang der Seite mit passenden Schlagwörtern zu einem Ergebnis gelangen. Eine Referenz zeigt an, dass das gefundene Transfektionsreagenz bereits erfolgreich für die entsprechende Anwendung verwendet wurde. Im Idealfall sind getestete Transfektionsparameter und Transfektionseffizienzen angegeben.
Keine Referenz? > Allgemeine Auswahlhilfe
Wenn Sie keine Referenz gefunden haben, heißt das nicht, dass kein passendes Reagenz zur Verfügung steht, sondern lediglich, dass bisher keine Erfahrungsberichte vorliegen. In diesem Falle kann durch eine Vorauswahl ein erfolgsversprechendes Transfektionsreagenz ausgewählt (Allgemeine Auswahlhilfe) und letztendlich ausgetestet (Kostenlose Testsamples) werden. Wenn Sie einen Erfahrungsbericht für uns schreiben möchten machen wir Ihnen ein Angebot für eine Gegenleistung.
CELL TYPE | DESCRIPTION OF CELL TYPE | CAT.NO. | SPECIES | ORIGIN OF CELLS | COMMON CELL TYPE | GROWTH PROPERTIES | NUCLEIC ACID / DELIVERED MOLECULE | APPLICATION | PRODUCT | REFERENCE TYPE | BIBLIOGRAPHIC DATA | LINK | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
H4 |
Human neuroglioma cells | ATCC HTB148 | Human | brain | unknown | adherent | plasmid | Metafectene | publication | T. Lopes da Fonseca et al., Hum. Mol. Genet., Jun 2016; 10.1093/hmg/ddw147 | Link | ||
H4 |
Human neuroglioma cell line | ATCC HTB148 | Human | brain | cell line | adherent | plasmid | Metafectene | publication | K. Albert et al., Mol. Therapy, 2021, 29: 9, doi.org/10.1016/j.ymthe.2021.04.035 | Link | ||
H413 |
Human oral squamous cell carcinoma cell line | Human | digestive organs | cell line | adherent | plasmid | Metafectene PRO | publication | N. Düzgünes et al., Methods in Enzymology, 2012, 509, DOI: 10.1016/B978-0-12-391858-1.00018-6 | ||||
H413 |
Human oral squamous cell carcinoma cell line | Human | digestive organs | cell line | adherent | plasmid | Metafectene | publication | K. Konopka et al., Cell Mol Biol Lett, Jan 2009; 14(1): 70-89 | ||||
HaCaT |
Human epidermal keratinocyte cell line | Human | skin | cell line | adherent | plasmid | K2 Transfection System | publication | V. Morales-Garcia et al., FEBS Open Bio 10, 2020, 2541–2552, doi:10.1002/2211-5463.12987 | ||||
HaCaT |
Human epidermal keratinocyte cell line | Human | skin | cell line | adherent | plasmid | Metafectene | publication | E. Xu et al., Mol. Cancer Res., 2014, 12(3):359-369, DOI: 10.1158/1541-7786.MCR-13-0526 | Link | |||
HaCaT |
Human epidermal keratinocyte cell line | Human | skin | cell line | adherent | plasmid | Metafectene | publication | N. Motsch et al., PLoS ONE 7(8): e42193, doi:10.1371/journal.pone.0042193 | Link | |||
HaCaT |
Human epidermal keratinocyte cell line | Human | skin | cell line | adherent | plasmid | Metafectene PRO | publication | L. Stixová et al., Life, 2021, 11, 669, doi.org/10.3390/life11070669 | Link | |||
HaCaT |
Human epidermal keratinocyte cell line | Human | skin | cell line | adherent | plasmid | Metafectene PRO | publication | W. Xiao et al., Free Radical Biology and Medicine, 2013, 65: 70–77, doi.org/10.1016/j.freeradbiomed.2013.06.010 | ||||
HaCaT |
Human epidermal keratinocyte cell line | Human | skin | cell line | adherent | plasmid | K4 Multiplier | publication | Z. Regdon et al., Br. J. Pharmacol.,2021, 178: 1095–1113, DOI: 10.1111/bph.15344 | Link | |||
HaCatT |
Human epidermal keratinocyte cell line | Human | skin | cell line | adherent | plasmid | K2 Transfection System | publication | S. Sominsky et al., Virology, 2014, 468-470: 510-523, doi.org/10.1016/j.virol.2014.09.007 | Link | |||
HaCatT |
Human epidermal keratinocyte cell line | Human | skin | cell line | adherent | plasmid | K2 Transfection System | publication | Y.-S. Kim, Poster 222, Active Material:Organic & Natural, iloveweb.kr | Link | |||
hADMC |
Human primary adipose-derived mast cells | Human | immune system | primary cell | plasmid | Metafectene PRO | publication | M. Motaghed et al., J. Immuntherapy of Cancer, 2021, 9(Suppl 2): A1–A1052, doi.org/10.1136/jitc-2021-SITC2021.220 | Link | ||||
hASMC |
Human arterial smooth muscle cells | Human | vasculature | unknown | siRNA | RNA-Interference | Metafectene SI | publication | M. R. Schroeter et al., Cardiovasc Res, Aug 2013; 99: 555 - 565 | Link | |||
hBCSCs |
Human breast cancer stem cells (from xenografts of human breast cancers) | Human | respiratory system | stem cell | adherent | siRNA | RNA-Interference | Metafectene SI | publication | W.-W. Chang et al., Breast Cancer Res., 2013, 15: R39, doi:10.1186/bcr3423 | Link | ||
HBL 100 |
Human transformed epithelial cell line | Human | breast | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | A. M. Scherbakov et al., Exp. Cell Res., 2013, 319: 3150 – 3159, doi.org/10.1016/j.yexcr.2013.08.019 | |||
HBL 100 |
Human transformed epithelial cell line | Human | breast | cell line | adherent | plasmid | cotransfection (plasmid/siRNA) | Metafectene PRO | publication | A. M. Scherbakov et al., Exp. Cell Res., 2013, 319: 3150 – 3159, doi.org/10.1016/j.yexcr.2013.08.019 | |||
HBL 100 |
Human transformed epithelial cell line | Human | breast | cell line | adherent | siRNA | cotransfection (plasmid/siRNA) | Metafectene PRO | publication | A. M. Scherbakov et al., Exp. Cell Res., 2013, 319: 3150 – 3159, doi.org/10.1016/j.yexcr.2013.08.019 | |||
HBL 100 |
Human transformed epithelial cell line | Human | breast | cell line | adherent | plasmid | cotransfection (plasmid/plasmid) | Metafectene PRO | publication | A. M. Scherbakov et al., Exp. Cell Res., 2013, 319: 3150 – 3159, doi.org/10.1016/j.yexcr.2013.08.019 | |||
HBL 100 |
Human transformed epithelial cell line | Human | breast | cell line | adherent | plasmid | Metafectene | publication | A. M. Scherbakov et al., J. of Cellular Biochem., 2012, 113: 2147–2155 | ||||
hBMSC |
Human bone marrow-derived mesenchymal stem cells | Human | bone | primary cell | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | E. J. Lee et al., Mol. Therapy, 2017, 26(3): 845-859, doi.org/10.1016/j.ymthe.2017.12.015 | Link | ||
hBMSC |
Human bone marrow-derived mesenchymal stem cells | Human | bone | stem cell | adherent | siRNA | Metafectene PRO | publication | E. J. Lee, Mol. Therapy, 2018, doi: 10.1016/j.ymthe.2017.12.015 | ||||
hBMSC |
Human bone marrow-derived mesenchymal stem cells | Human | bone | stem cell | adherent | plasmid | Metafectene | publication | D. Malik et al., PLoSONE, 13(9):e0203614, doi.org/10.1371/journal.pone.0203614 | Link | |||
HCC-44 |
Human lung adenocarcinoma cell line | Human | respiratory system | cell line | adherent | plasmid | Metafectene PRO | publication | J. Berrout et al., Nature Communications, 2017,8: 947, DOI: 10.1038/s41467-017-00983-w | Link | |||
HCC-515 |
Human lung adenocarcinoma cell line | Human | respiratory system | cell line | adherent | plasmid | Metafectene PRO | publication | J. Berrout et al., Nature Communications, 2017,8: 947, DOI: 10.1038/s41467-017-00983-w | Link |